Podcasts about Barata

Dr. Pedro Barata and Dr. Rana McKay discuss the integration of innovative advances in molecular imaging and therapeutics to personalize treatment for patients with renal cell and urothelial carcinomas. TRANSCRIPT Dr. Pedro Barata: Hello, I'm Dr. Pedro Barata, your guest host of By the Book, a podcast series featuring insightful conversations between authors and editors of the ASCO Educational Book. I'm a medical oncologist at University Hospitals Seidman Cancer Center and an associate professor of medicine at Case Western Reserve University in Cleveland, Ohio. I'm also an associate editor of the ASCO Educational Book. Now, we all know the field of genitourinary cancers (GU) is evolving quite rapidly, and we have new innovations in molecular imaging as well as targeted therapeutics. Today's episode will be exploring novel approaches that are transforming the management of renal cell and urothelial carcinomas and also their potential to offer a more personalized treatment to patients. For that, joining for today's discussion is Dr. Rana McKay, a GU medical oncologist and professor at University of California San Diego. Dr. McKay will discuss her recently published article titled, “Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.”  Our full disclosures are available in the transcript of this episode.  And with that, Rana McKay, great to have you on the podcast today. Dr. Rana McKay: Oh, thank you so much, Dr. Barata. It's really wonderful to be here with you. So, thanks for hosting. Dr. Pedro Barata: No, thanks for taking the time, and I'm looking forward to this conversation. And by the way, let me start by saying congrats on a great article in the Educational Book. Really super helpful paper. I'm recommending it to a lot of the residents and fellows at my own institution. I would like to first ask you to kind of give our listeners some context of how novel approaches in the molecular imaging as well as targeted therapeutics are actually changing the way we're managing patients with GU, but specifically with renal cell carcinoma and urothelial carcinoma. So, what are the areas you would call out as like being big areas for innovation in this context, and why are they important? Dr. Rana McKay: Very good question. And I think this is really what this article highlights. It highlights where are we going from an imaging diagnostics standpoint? Where are we going from a therapeutic standpoint? And I think if we have to step back, from the standpoint of diagnostics, we've seen PET imaging really transform diagnostics in prostate cancer with the advent of PSMA PET imaging, and now PSMA PET imaging is used as a biomarker for selection for theranostics therapy. And so, we're starting to see that enter into the RCC landscape, enter into the urothelial cancer landscape to a lesser extent. And I think it's going to potentially be transformative as these tools get more refined. I think when we think about therapeutics, what's been transformative most recently in the renal cell carcinoma landscape has been the advent of HIF2α inhibition to improve outcomes for patients. And we have seen the approval of belzutifan most recently that has reshaped the landscape. And now there's other HIF2α inhibitors that are being developed that are going to be further important as they get refined. And lastly, I think when we think about urothelial carcinoma, the greatest transformation to treatment in that context has been the displacement of cisplatin and platinum-based chemotherapy as a frontline standard with the combination of enfortumab vedotin plus pembrolizumab. And we've seen antibody-drug conjugates really reshape treatment and tremendously improve outcomes for patients. So, I think those are the three key areas of interest. Dr. Pedro Barata: So with that, let's focus first on the imaging and then we'll get to the therapeutic area. So, we know there's been a paradigm shift, really, when prostate-specific targets emerged as tracers for PET scanning. And so, we now commonly use prostate-specific membrane antigen, or PSMA-based PET scanning, and really transform how we manage prostate cancer. Now, it appears that we're kind of seeing a similar wave in renal cell carcinoma with the new radiotracer against the target carbonic anhydrase IX. What can you tell us about this? And is this going to be available to us anytime soon? And how do you think that might potentially change the way we're managing patients with RCC today? Dr. Rana McKay: First, I'll step back and say that in the context of PSMA PET imaging, we have actually been able to better understand RCC as well. So, we know that PSMA is expressed in the neovasculature of tumors, and it can actually be used to detect renal cell carcinoma tumors. It has a detection rate of about 84% when used for detection. And so, you know, I don't think it's just restricted to carbonic anhydrase IX, but we will talk about that. So, PSMA expressed in the neovasculature has a detection rate of around 84%, particularly if we're looking at clear cell RCC. CAlX is overexpressed in clear cell RCC, and it's actually used in diagnosing renal cell carcinoma when we think of CAlX IHC for diagnosing clear cell RCC. And now there are CAlX PET tracers. The first foray was with the ZIRCON study that was actually an interestingly designed study because it was designed to detect the likelihood of PET imaging to identify clear cell RCC. So, it was actually used in the early diagnostics setting when somebody presents with a renal mass to discriminate that renal mass from a clear cell versus a non-clear cell, and it was a positive study. But when I think about the potential application for these agents, you know, I think about the entire landscape of renal cell carcinoma. This is a disease that we do treat with metastasis-directed therapy. We have certainly seen patients who've undergone metastasectomy have long, durable remissions from such an approach. And I think if we can detect very early onset oligometastatic disease where a metastasis-directed therapy or SABR could be introduced - obviously tested in a trial to demonstrate its efficacy - I think it could potentially be transformative. Dr. Pedro Barata: Wonderful. It's a great summary, and I should highlight you are involved in some of those ongoing studies testing the performance of this specific PET scanning for RCC against conventional imaging, right? And to remind the listeners, thus far, for the most part, we don't really do FDG-PET for RCC. There are some specific cases we do, but in general, they're not a standard scanning. But maybe that will change in the future. Maybe RCC will have their own PSMA-PET. And to your point, there's also emerging data about the role of PSMA-PET scanning in RCC as well, as you very elegantly summarized. Wonderful. So, let me shift gears a little bit because you did, in your introduction, you did highlight a novel MOA that we have in renal cell carcinoma, approved for use, initially for VHL disease, and after that for sporadic clear cell renal cell carcinoma. We're talking about hypoxia-inducible factor 2-alpha inhibitors, or HIF2α inhibitors, such as belzutifan. But there's also others coming up. So, as a way to kind of summarize that, what can you tell us about this breakthrough in terms of therapeutic class, this MOA that got to our toolbox of options for patients with advanced RCC? Tell us a little bit what is being utilized currently in the management of advanced RCC. And where do you see the future going, as far as, is it moving early on? Is it getting monotherapy versus combinations? Maybe other therapies? What are your thoughts about that? What can you tell us about it? Dr. Rana McKay: Belzutifan is a first-in-class HIF2α inhibitor that really established clinical validation for HIF2α as a therapeutic target. When we think about the activity of this agent, the pivotal LITESPARK-005 trial really led to the approval of belzutifan in patients who were really heavily pretreated. It was patients who had received prior IO therapy, patients who had received prior VEGF-targeted therapy. And in the context of this study, we saw a median PFS of 5.6 months, and there did seem to be a tail on the curve when you looked at the 12-month PFS rate with belzutifan. It was 33.7% compared to 17.6% with everolimus. And then when we look at the response rate, it was higher with belzutifan on the order of 22-23%, and very low with everolimus, as we've previously seen. I think one of the Achilles heels of this regimen is the primary PD rate, which was 34% when used in later line. There are multiple studies that are testing belzutifan in combination across the treatment landscape. So, we have LITESPARK-011, which is looking at the combination of belzutifan plus lenvatinib in the second-line setting. We've got the MK-012 [LITESPARK-012] study, which is looking at belzutifan in various combinations in the frontline setting. So there is a combination with IO plus belzutifan. And so this is also being looked at in that context. And then we also have the LITESPARK-022 study, which is looking at pembrolizumab with belzutifan in the adjuvant setting. So there's a series of studies that will be exploring belzutifan really across the treatment landscape. Many of these studies in combination. Additionally, there are other HIF2α inhibitors that are being developed. We have casdatifan, which is another very potent HIF2α inhibitor. You know, I think pharmacologically, these are different agents. There's a different half-life, different dosing. What is going to be the recommended phase 3 dose for both agents, the EPO suppression levels, the degree of EPO suppression, and sustainability of EPO suppression is very different. So, I think we've seen data from casdatifan from the ARC-20 trial from monotherapy with a respectable response rate, over 30%, primary PD rate hovering just around 10%.  And then we've also seen data of the combination of casdatifan with cabozantinib as well that were recently presented this year. And that agent is also being tested across the spectrum of RCC. It's being looked at in combination with cabozantinib in the PEAK-1 study, and actually just at the KCRS (Kidney Cancer Research Summit), we saw the unveiling of the eVOLVE-RCC trial, which is going to be looking at a volrustomig, which is a PD-1/CTLA-4 inhibitor plus casdatifan compared to nivo-ipi in the frontline setting.  So, we're going to see some competition in this space of the HIF2α inhibitors. I think when we think of mechanism of action in that these are very potent, not a lot of off-target activity, and they target a driver mutation in the disease. And that driver mutation happens very early in the pathogenesis. These are going to be positioned much earlier in the treatment landscape. Dr. Pedro Barata: All these studies, as you're saying, look really promising. And when we talk about them, you mentioned a lot of combinations. And to me, when I think of these agents, it makes a lot of sense to combine because there's not a lot of overlapping toxicities, if you will. But perhaps for some of our listeners, who have not used HIF2α inhibitors in practice yet, and they might be thinking about that, what can you tell us about the safety profile? How do you present it to your patients, and how do you handle things like hypoxia or anemia? How do you walk through the safety profile and tolerability profile of those agents like belzutifan? Dr. Rana McKay: I think these drugs are very different than your traditional TKIs, and they don't cause the classic symptoms that are associated with traditional TKIs that many of us are very familiar with like the rash, hand-foot syndrome, hypertension, diarrhea. And honestly, these are very nuanced symptoms that patients really struggle with the chronicity of being on a chronic daily TKI. The three key side effects that I warn patients about with HIF2α inhibitors are: (1) fatigue; (2) anemia; and (3) hypoxia and dysregulation in the ability to sense oxygen levels. And so, many of these side effects - actually, all of them - are very dose-dependent. They can be very well-managed. So, we can start off with the anemia. I think it's critically important before you even start somebody on belzutifan that you are optimizing their hemoglobin and bone marrow function. Make sure they don't have an underlying iron deficiency anemia. Make sure they don't have B12 or folate deficiency. Check for these parameters. Many patients who have kidney cancer may have some hematuria, other things where there could be some low-level blood loss. So, make sure that those are resolved or you're at least addressing them and supplementing people appropriately. I monitor anemia very closely every 3 to 4 weeks, at least, when people start on these medications. And I do initiate EPO, erythropoietin, should the anemia start to worsen. And I typically use a threshold of around 10g/dL  for implementing utilization of an EPO agent, and that's been done very safely in the context of the early studies and phase 3 studies as well. Now, with regards to the hypoxia, I think it's also important to make sure that you're selecting the appropriate individual for this treatment. People who have underlying COPD, or even those individuals who have just a very high burden of disease in their lung, lymphangitic spread, pleural effusions, maybe they're already on oxygen - that's not an ideal candidate for belzutifan. Something that very easily can be done in the clinic before you think about initiating somebody on this treatment, and has certainly been integrated into some of the trials, is just a 6-minute walk test. You know, have the patient walk around the clinic with one of the MAs, one of the nurses, put the O2 sat on [measuring oxygen saturation], make sure they're doing okay. But these side effects, like I said, are very dose-dependent. Typically, if a patient requires, if the symptoms are severe, the therapy can be discontinued and dose reduced. The standing dose is 120 mg daily, and there's two dose reductions to 80 mg and 40 mg should somebody warrant that dose modification. Dr. Pedro Barata: This is relatively new, right? Like, it was not that we're used to checking oxygen levels, right? In general, we're treating these patients, so I certainly think there's a learning curve there, and some of the points that you highlight are truly critical. And I do share many of those as well in our practice. Since I have you, I want to make sure we touch base on antibody-drug conjugates as well. It's also been a hot area, a lot of developments there. When I think of urothelial carcinoma and renal cell carcinoma, I see it a little bit different. I think perhaps in urothelial carcinoma, antibody-drug conjugates, or ADCs, are somewhat established already. You already mentioned enfortumab vedotin. I might ask you to expand a little bit on that. And then in renal cell carcinoma, we have some ADCs as well that you include in your chapter, and that I would like you to tell us what's coming from that perspective. So, tell us a little bit about how do you see ADCs in general for GU tumors, particularly UC and RCC? Tell us a little bit about the complexity or perhaps the challenges you still see. At the same time, tell us about the successes. Dr. Rana McKay: Stepping back, let's just talk about like the principles and design of ADCs. So, most ADCs have three components. There's a monoclonal antibody that typically targets a cell surface antigen, which is conjugated by a linker, which is the second component, to a payload drug. And typically, that payload drug has been chemotherapy, whether it be topoisomerase or whether it be MMAE or other chemotherapeutic. We can start in the RCC space. There's been multiple antibody-drug conjugates that have been tested. There's antibody-drug conjugates to CD70, which is expressed on clear cell RCC. There's been antibody-drug conjugates to ENPP3, which is also expressed on RCC. There's antibody-drug conjugates to CDH6. And they have different payloads, like I said, whether it be topoisomerase I or other microtubule inhibitors. Now, when we think about kidney cancer, we don't treat this disease with chemotherapy. This disease is treated with immunotherapy. It is treated with treatments that target the VEGF pathway and historically has not been sensitive to chemo. So, I think even though the targets have been very exciting, we've seen very underwhelming data regarding activity, and in some context, seen increased toxicity with the ADCs. So, I think we need to tread lightly in the context of the integration and the testing of ADCs in RCC. We just came back from the KCRS meeting, and there was some very intriguing data about a c-Kit ADC that's being developed for chromophobe RCC, which is, you know, a huge unmet need, these variant tumors that really lack appropriate therapeutics. But I just caution us to tread lightly around how can we optimize the payload to make sure that the tumor that we're treating is actually sensitive to the agent that's targeting the cell kill. So, that's a little bit on the ADCs in RCC. I still think we have a long way to go and still in early testing. Now, ADCs for UC are now the standard of care. I think the prototypical agent, enfortumab vedotin, is a nectin-4-directed ADC that's conjugated to an MMAE payload and was the first ADC approved for advanced urothelial, received accelerated approval following the EV-201 trial, which was basically a multicenter, single-arm study that was investigating EV in cisplatin-ineligible patients with advanced urothelial carcinoma, and then ultimately confirmed in the EV-301 study as well. And so, that study ended up demonstrating the support superiority of EV from an overall survival standpoint, even PFS standpoint. Building on that backbone is the EV-302 study, which tested EV in combination with pembrolizumab versus platinum-based chemotherapy in the frontline setting. And that was a pivotal, landmark study that, like I said, has displaced platinum therapy as a frontline treatment for people with advanced urothelial carcinoma. And when we think about that study and the median overall survival and just how far we've come in urothelial cancer, the median OS with EV-pembro from that trial was 31 and a half months. I mean, that's just incredible. The control arm survival was 16 and a half months. The hazard ratio for OS, 0.47. I mean this is why when this data was presented, it was literally a standing ovation that lasted for several minutes because we just haven't seen data that have looked that good. And there are other antibody-drug conjugates that are being tested. We've all been involved in the saga with sacituzumab govitecan, which is a trophoblast cell surface antigen 2 (Trop-2) targeted ADC with a topoisomerase I payload. It was the second ADC to receive approval, but then that approval was subsequently withdrawn when the confirmatory phase 3 was negative, the TROPiCS-04 trial. So, approval was granted based off of the TROPHY-U-01, single-arm, phase 2 study, demonstrating a response rate of around 28% and a PFS of, you know, about 5 and a half months. But then failure to show any benefit from an OS standpoint. And I think there's a lot of controversy in the field around whether this agent still has a role in advanced urothelial carcinoma. And I think particularly for individuals who do not have molecular targets, like they're not HER2-amplified or have HER2-positivity or FGFR or other things like that. Dr. Pedro Barata: Fantastic summary, Rana. You were talking about the EV, and it came to mind that it might not be over, right, for the number of ADCs we use in clinical practice in the near future. I mean, we've seen very promising data for ADC against the HER2, right, and over-expression. It also can create some challenges, right, in the clinics because we're asking to test for HER2 expression. It's almost like, it's not exactly the same to do it in breast cancer, but it looks one more time that we're a little bit behind the breast cancer field in a lot of angles. And also has vedotin as a payload. Of course, I'm referring to disitamab vedotin, and there's very elegant data described by you in your review chapter as well. And it's going to be very interesting to see how we sequence the different ADCs, to your point as well. So, before we wrap it up, I just want to give you the opportunity to tell us if there's any area that we have not touched, any take-home points you'd like to bring up for our listeners before we call it a day. Dr. Rana McKay: Thank you so much. I have to say, you know, I was so excited at ASCO this year looking at the GU program. It was fantastic to see the progress being made, novel therapeutics that really there's a tremendous excitement about, not just in RCC and in UC, but also in prostate cancer, thinking about the integration of therapies, not just for people with refractory disease that, even though our goal is to improve survival, our likelihood of cure is low, but also thinking about how do we integrate these therapies early in the treatment landscape to enhance cure rates for patients, which is just really spectacular. We're seeing many of these agents move into the perioperative setting or in combination with radiation for localized disease. And then the special symposium on biomarkers, I mean, we've really come a long, long way. And I think that we're going to continue to evolve over the next several years. I'm super excited about where the field is going in the treatment of genitourinary malignancies. Dr. Pedro Barata: Oh, absolutely true. And I would say within the Annual Meeting, we have outstanding Educational Sessions. And just a reminder to the listeners that actually that's where the different teams or topics for the Educational Book chapters come from, from actually the educational sessions from ASCO. And your fantastic chapter is an example of that, right, focusing on advanced GU tumors. So, thank you so much, Rana, for taking the time, sharing your insights with us today on the podcast. It was a fantastic conversation as always. Dr. Rana McKay: My pleasure. Thanks so much for having me, Dr. Barata. Dr. Pedro Barata: Of course.  And thank you to our listeners for your time today. You will find the link to the article discussed today in the transcript of this episode. I also encourage you to check out the 2025 ASCO Educational Book. You'll find an incredible wealth of information there. It's free, available online, and you'll find, hopefully, super, super important information on the key science and issues that are shaping modern oncology, as we've heard from Dr. McKay and many other outstanding authors. So, thank you, everyone, and I hope to see you soon. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Pedro Barata @PBarataMD Dr. Rana McKay @DrRanaMcKay Follow ASCO on social media:        @ASCO on X (formerly Twitter)        ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:     Dr. Pedro Barata: Stock and Other Ownership Interests: Luminate Medical Honoraria: UroToday Consulting or Advisory Role: Bayer, BMS, Pfizer, EMD Serono, Eisai, Caris Life Sciences, AstraZeneca, Exelixis, AVEO, Merck, Ipson, Astellas Medivation, Novartis, Dendreon Speakers' Bureau: AstraZeneca, Merck, Caris Life Sciences, Bayer, Pfizer/Astellas Research Funding (Inst.): Exelixis, Blue Earth, AVEO, Pfizer, Merck  Dr. Rana McKay: Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion, Calithera, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seattle Genetics, Telix, Eli Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, Astrazeneca, Myovant Research Funding (Inst.): Bayer, Tempus, AstraZeneca, Exelixis, Bristol Myers Squibb, Oncternal Therapeutics, Artera    

Oferta de milho e farelo aumentou e gerou oportunidade de negócios tanto para a pecuária de leite quanto de corte

Oferta de milho e farelo aumentou e gerou oportunidade de negócios tanto para a pecuária de leite quanto de corte

Hoje o papo é sobre BBB: beleza boa e barata!

Livros: https://Hotm.art/domine-as-redes-sociais Camisa: https://umapenca.com/juntosaobilhao Audiobook: https://bit.ly/escuteaudiobook Livros na Amazon: https://amzn.to/3I6uZXE Leia grátis: https://amzn.to/49MkDbH

CAPA V-DIAMOND BANSK – VIDRO TEMPERADO FOSCO BLINDADO: https://r.vocemaisrico.com/a204b40b43ENTRE NA LISTA DE ESPERA PARA O VIVER DE RENDA: https://r.vocemaisrico.com/275c54667cBitybank é a corretora do Bruno Perini para comprar Bitcoin - abra sua conta: https://r.vocemaisrico.com/0e566a9fff2025 começou carregando as marcas deixadas pelo ano anterior, período em que a bolsa caiu e o dólar disparou, superando a casa dos R$ 6.O cenário que se desenhou neste ano trouxe mudanças significativas: o Banco Central se viu obrigado a elevar os juros ao maior patamar desde 2006, a inflação segue pressionada e dificilmente baterá a meta, enquanto o real ganhou força frente ao dólar.No campo político e internacional, houve a intervenção de Donald Trump na economia, impondo tarifas a países aliados e aplicando ao Brasil alíquotas de até 50% em alguns produtos. No plano interno, embates entre Legislativo e Judiciário e a prisão de um ex-presidente aumentaram a tensão institucional.Diante de tudo isso, como enxergar o cenário até o final de 2025 — e, mais importante, como se preparar para 2026?Para responder estas e mais perguntas e te ajudar a decidir onde investir o seu dinheiro, convidamos os analistas Guilherme Cadonhotto, Felipe Arrais e Ricardo Figueiredo para o episódio nº 256 do podcast Os Sócios. Falaremos sobre estratégias de investimentos, cenário macroeconômico, oportunidades, riscos e muito mais.

Veracruz, con la canasta básica más barata y Juárez, la más cara: Profeco  Trump enviará Guardia Nacional a Washington D.C.Más información en nuestro podcast

In this episode of ASTCT Talks, Dr. Corey Cutler sits down with Dr. Anna Barata to discuss the critical role of physician-patient communication in GVHD and stem cell transplantation. Together, they unpack the complex emotional and psychological landscape facing transplant survivors and the communication barriers that often go unspoken. Dr. Barata shares insights into the challenges faced by both patients and providers, ranging from unspoken anxiety and cognitive dysfunction to hesitations around discussing complementary therapies. This episode offers a look at how better communication can transform the transplant experience, making space for shared decision-making, emotional support and truly patient-centered care. 

En un escenario global de creciente volatilidad comercial, donde Estados Unidos ha implementado nuevas medidas arancelarias que impactan a diversas naciones, Colombia emerge con una posición que, si bien no es la ideal, es comparativamente ventajosa con respecto a otros países.See omnystudio.com/listener for privacy information.

Alexandre de Moraes foi enquadrado na Lei Magnitsky. Os bolsonaristas estão eufóricos. Mas, olha, saiu também a lista das tarifas americanas contra o Brasil. A montanha pariu um rato. E o resultado disso tudo vai ser picanha barata no prato dos brasileiros, Lula fortalecido e, acreditem, os Estados Unidos enfraquecidos.See omnystudio.com/listener for privacy information.

Reouça ao comentário de #PolíticaJG, direto de Brasília (DF), com Josias de Souza. #JornalDaGazeta

¿Cómo puede ser que la vivienda libre cueste MENOS que la vivienda protegida (VPO) en algunas zonas de España? ¿No se suponía que el Estado estaba para proteger a los más vulnerables? Pues spoiler: lo está haciendo todo al revés.

Valeria Moy, analista

Los denominados incendios de sexta generación como el ocurrido recientemente en Lleida hacen saltar las alarmas sobre su control ya que son realmente agresivos e impredecibles. Para explicar su origen y características el catedrático de Ingeniería Forestal de la Universidad de Lleida Víctor Resco de Dios ha estado presente en Las Mañanas de RNE: "El concepto de sexta generación es todavía más rápido y más intenso que los incendios normales". Los motivos de su aparición según el catedrático se deben "al abandono rural que ha producido un aumento del combustible para las llamas".La clave según Víctor Resco de Dios para evitar este tipo de incendios "es crear una especie de paisajes heterogéneos porque lo que a los incendios les va mejor es un paisaje continuo y homogéneo donde tenga mucha carga de combustible seco". Pero ante este rediseño del paisaje señala que "hay un problema económico mal entendido porque la prevención es más barata que la extinción y un problema político, que necesitamos que tomen las medidas para que esto se lleve adelante y con esta presión social en contra es muy difícil encontrar a estos gestores". En última instancia, lo que esta situación provoca es "favorecer que el problema de los incendios se agrave porque no hacer nada sale gratis, mientras que el hacer algo conlleva un riesgo de que la opinión social se ponga en contra del político".Escuchar audio

Quick Synopsis (appears in most podcast apps)In 1772 Portugal, an 18-year-old caregiver named Luísa de Jesus turned the era's child-welfare “foundling wheel” into a murderous money scheme. Before authorities intervened, at least 33 abandoned infants lay buried on Monte Arroio or hidden beneath her cottage floorboards. We expose the systemic cracks, the killer's psychology, and the reforms her crimes set in motion. Episode Breakdown00:00 Opening scene on Monte Arroio04:15 How foundling wheels worked—and failed09:02 Luísa's early life & public façade15:30 The money trail: 600 réis per child22:47 Forensic discoveries: graves & hidden clay pots30:18 Confession to 28 murders36:55 Trial, garrote, and public execution43:20 Child-welfare reforms that followed48:05 Today's take-aways on safeguarding the vulnerableWhy This Case Still ResonatesFirst female serial killer executed in Portugal—and the last woman ever put to death there.Exposed lethal flaws in 18th-century child-protection policy, triggering nationwide reform.Challenges myths that women “only poison”; Luísa strangled newborns for profit.A cautionary tale of how financial incentives plus lax oversight can weaponize charity.Fast FactsYears active: 1771–1772Confirmed victims: 33 infants (one child remains unaccounted for) Method: Strangulation or suffocation within days of state payoutMotive: Collecting stipends meant for wet nursesSentence: Hands severed, garroted; body burned, ashes scattered (1 July 1772)Sources & Further ReadingNational Archives, “Casa da Roda” foundling-wheel records, 1760-1775António Barata, Infanticídio e Justiça em Portugal Setecentista (2018)Royal Chancellery of Coimbra trial transcripts, 1772–1773Stay ConnectedFollow & subscribe on Apple Podcasts, Spotify, or your preferred app.Rate & review—it helps other ethical true-crime fans find us.SEO KeywordsLuísa de Jesus, Foundling Wheel Killer, Coimbra infanticide, 18th-century serial killer, female serial killer history, child-welfare reform, Foul Play podcastMyths & Malice illuminates truth with empathy. Thank you for listening.Support this podcast at — https://redcircle.com/foul-play-crime-series/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Neste episódio do Café com Leite, Bárbara e Babica trazem a divertida e sábia história da formiga e da barata. Enquanto a formiga trabalha sem parar, guardando grão por grão para o futuro, a barata desperdiça, faz bagunça e depois fica na mão. Uma fábula cheia de lições sobre trabalho, planejamento, responsabilidade e independência, contada de um jeito leve e envolvente para crianças e suas famílias. Vamos juntos aprender com esses pequenos insetos?

Los misiles Shahed de fabricación iraní han evolucionado significativamente en su uso por parte de Rusia, especialmente en el contexto del conflicto en Ucrania. Inicialmente, los Shahed-136, conocidos como "drones kamikaze", eran dispositivos de bajo coste y diseño simple, pero eficaces para ataques de saturación gracias a su capacidad para operar en enjambre. Estos drones, con alcances de hasta 2500 km y cargas explosivas de 50 kg, destacaban por su asequibilidad y facilidad de producción. Sin embargo, su simplicidad los hacía vulnerables a las defensas aéreas modernas, lo que llevó a Rusia a buscar mejoras.

¿Al fin tendremos una Macbook barata? ¿Será que no queramos ver a Windows nunca más? ¿Este es otro podcast solo de apple?… Dale play y entérate mi bro porque tenemos mucho que contarte y el de los copys no te lo va a reseñar.

En este episodio hablamos de ese estímulo rápido y fácil que nos dan las redes sociales, los reels infinitos y las notificaciones que suenan cada cinco minutos. ¿Por qué ya no sabemos ir al baño sin el teléfono? ¿podríamos trotar o salir a caminar sin audífonos? ¿Qué es realmente la dopamina y cómo la sobreestimulación nos está deprimiendo y convirtiendo en zombies? Exploramos la diferencia entre la dopamina buena y la mala, técnicas para usar menos el celular y cómo recuperar la concentración y la motivación real.Únete a Patreon para contenido Exclusivo: https://www.patreon.com/c/laparejamasaburridadelmundo

Olá! Você está ouvindo o Espiadinha, o podcast que tem 70 câmeras e o Brasil tá vendo! Eu sou o Athilas, e hoje estaremos comentando todos os acontecimentos e detalhes do Power Couple Brasil 7!Mande sua opinião: https://livepix.gg/espiadinhapodcastSiga o Espiadinha nas redes sociais!Facebook:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ https://web.facebook.com/EspiadinhaPodcast/?_rdc=1&_rdrInstagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://instagram.com/espiadinhapodcast#PowerCoupleBrasil #PowerCouple #PowerCoupleBR

Projeto da Universidade de Coimbra está a desenhar uma rede europeia para o ensino da meteorologia espacial.

Bienvenidos a un nuevo episodio de Al Corte Podcast.Hoy charlamos con Joseba, CEO de EasyGas, una de las cadenas de gasolineras independientes más conocidas en España en redes sociales.En este episodio repasamos su historia personal en el sector, cómo llegó a montar su propia red de estaciones de servicio, y sobre todo, destapamos todos los mitos sobre la gasolina, el diésel, los aditivos y el negocio del repostaje.En este episodio hablamos de:✅ ¿Es verdad que la gasolina low cost daña el motor?✅ Cómo funciona realmente el negocio del combustible✅ La guerra de precios y márgenes en las gasolineras✅ Lo que las grandes marcas no quieren que sepas✅ Aditivos, calidad y manipulación: verdades y mentiras del surtidorUn episodio que cambia tu forma de ver lo que pones en el depósito.----------------------------

Em altura de Santos Populares, a OPEN AI vai baixar preço das subscrições do Modelos de Linguagem em 80%. Neste programa falamos sobre as diferenças entre IA "gratuíta" e paga.See omnystudio.com/listener for privacy information.

A Bolsa está barata? Ou só parece?As utilities subiram 40% e o Ibovespa não mostra a real foto da Bolsa. Fundos de valor perderam espaço. Os fundos de momentum amplificaram os movimentos. O FOMO tomou conta da indústria. E ainda tem a eleição — que pode definir se a trajetória da dívida vai fechar ou explodir.É, num cenário desses, confiar só em narrativa pode custar caro.Por isso, o Stock Pickers convidou Gustavo Constantino, sócio e CIO da Távola Capital, uma das gestoras mais técnicas e criteriosas do mercado. Com a gente, ele discutiu se ainda faz sentido falar que a bolsa está barata, como a Távola tenta precificar o risco político no valuation dos ativos, e quais são hoje suas principais convicções.Uma aula sobre disciplina de valuation, análise de risco e como fugir da histeria coletiva do mercado.Aperta o play, porque esse episódio é pra quem realmente quer entender o jogo.________________PLANILHA AGENDA DE DIVIDENDOSAcompanhe datas de pagamento, data com e data ex com uma planilha gratuita e sempre atualizada: https://www.infomoney.com.br/conteudos/planilhas/agenda-de-dividendos/?utm_source=youtube&utm_medium=canal-infomoney&utm_campaign=adi &utm_term=hiperlink&utm_content=descricao________________Cadastre-se e receba InfoMoney Premium, uma seleção única do melhor conteúdo produzido pelo maior ecossistema de informação financeira do Brasil: https://lps.infomoney.com.br/infomoney-premium-inscricao/?utm_source=youtube&utm_medium=canal-infomoney&utm_campaign=imp&utm_term=hiperlink&utm_content=descricao

Confira na edição do Jornal da Record News desta sexta-feira (6): preço da cesta básica cai em 15 de 17 capitais em maio. Lula destaca agro e acordo com a União Europeia em segundo dia na França. E mais: exportações de frango brasileiro despencam 12,9%.

Nessa edição do FlatOut Podcast, Juliano Barata, Leo Contesini e Marco Antônio Oliveira discutem sobre o novo Volkswagen Tera e o futuro da linha Volkswagen, e conhecem os detalhes do novo carro do MAO. Além disso, o Juliano Barata fala sobre como irá escolher seu próximo carro na Suécia.

Banco do Brasil com um problema "agudo" na carteira de crédito agro, Bradesco numa "vida nova" cheia de incertezas, "Fintechs" que cresceram muito mas apresentam dúvidas adiante, Itaú descolado de Itaúsa de uma forma difícil de explicar, BTG movimentando para virar incumbente e o IOF que pode mudar a história dos veículos de crédito...É, uma conversa com quem sabe opinar com propriedade sobre esses assuntos deveria ser imperdível, não é?O Stock Pickers convidou Pedro Gonzaga, sócio e analista responsável pela cobertura do setor financeiro na Mantaro Capital. Na dupla função de de convidado e co-apresentador: Matheus Guimarães, analista que cobre o mesmo setor na XP Research. Um episódio técnico, profundo. Um debate que o tema precisava - aperta o play!PLANILHA AGENDA DE DIVIDENDOS Acompanhe datas de pagamento, data com e data ex com uma planilha gratuita e sempre atualizada:https://www.infomoney.com.br/conteudos/planilhas/agenda-de-dividendos/?utm_source=youtube&utm_medium=canal-infomoney&utm_campaign=adi &utm_term=hiperlink&utm_content=descricao________________Cadastre-se e receba InfoMoney Premium, uma seleção única do melhor conteúdo produzido pelo maior ecossistema de informação financeira do Brasil:https://lps.infomoney.com.br/infomoney-premium-inscricao/?utm_source=youtube&utm_medium=canal-infomoney&utm_campaign=imp&utm_term=hiperlink&utm_content=descricao

Un estudiante de 19 años llamado Adam Kovalčík ha ganado $100.000 por encontrar una mejor manera de hacer medicina

Resumen de noticias de la mañana de LA NACION del 3 de junio de 2025 

Veja nesta edição que a gasolina fica 5,6% mais barata para distribuidoras a partir desta terça-feira (3). E mais: Lula embarca para a França para assinar acordos bilaterais.

Edição de 27 Maio 2025

Bom dia 247_ Luz mais barata para 100 milhões de brasileiros _22_5_25_ by TV 247

En esta ocasión, Carrusel de las Artes da una mirada al trabajo de la fotógrafa colombiana Isabella Madrid, quien explora en sus imágenes los códigos asociados a la feminidad colombiana o latinoamericana. Su serie se expone en el Festival Circulation(s) que se presenta en el centro cultural Le Centquatre de París.

In this episode, we talk about why Farmacias Similares is such a game-changer for healthcare in Mexico — from super cheap medications to quick, easy doctor visits. We also share a personal story about using their services and have some fun chatting about the famous Doctor Simi. If you've ever wondered how healthcare really works here, or just want to hear a few funny stories, this one's for you!Key Takeaways:How Farmacias Similares revolutionized healthcare affordability in MexicoWhy Doctor Simi became a symbol of trust and happinessThe huge convenience of their walk-in medical consultationsRelevant Links And Additional Resources:171 – Turismo Médico En México – Experiencias Y Costos | Medical Tourism In Mexico – Experiences And CostsLevel up your Spanish with our Podcast MembershipGet the full transcript of each episode so you don't miss a wordListen to an extended breakdown section in English going over the most important words and phrasesTest your comprehension with a multiple choice quizIf you enjoy Learn Spanish and Go, please consider subscribing, rating, and reviewing our podcast on Apple Podcasts, Spotify, Google Podcasts, or Pandora. This helps us reach more listeners like you. ¡Hasta la próximaSupport the show

En apenas 20 años, la plataforma china ha disparado el consumo de moda efímera con técnicas agresivas propias del juego online. Un experto en negocios y marketing digital nos explica los secretos del éxito masivo de Shein y los peligros que esconde su adictiva apariencia lúdica.

En apenas 20 años, la plataforma china ha disparado el consumo de moda efímera con técnicas agresivas propias del juego online. Un experto en negocios y marketing digital nos explica los secretos del éxito masivo de Shein y los peligros que esconde su adictiva apariencia lúdica.

Hoje a gente vai falar de um diretor que fraudou a Netflix em US$ 11 milhões, de um novo bug no YouTube, da marca de celulares Vivo que talvez esteja chegando no Brasil, do lançamento do Google Pixel 9a e também do Telegram falando que o WhatsApp não passa de uma cópia barata.

As notícias de hoje, que estão com os tempos marcados aqui embaixo são: Conheça o Vape-o-Gotchi, um Tamagotchi que usa nicotina para viver, Switch 2 custará R$ 4.000 no Brasil? Analistas prevêem que console terá o 'maior lançamento de todos os tempos', Meli+ Total, assinatura do Mercado Livre com streaming, fica mais barata, Encontre Meu Dispositivo agora permite compartilhar localização e Samsung anuncia data e primeiros aparelhos que terão a One UI 7. Boa noite e bem-vindos ao Hoje no TecMundo, o seu resumo diário de tecnologia!

00:00 Aprovação de Lula desaba00:22 Adeus à Lula impulsiona Ibovespa00:38 Mercado comemora queda de Lula00:50 O que o Lula vai fazer agora?01:30 Ibovespa01:53 Ações02:47 Eleições 202603:39 Contas Pública | Rombos Fiscais04:42 Dívida Pública05:24 Taxa de Juros | Selic 06:24 Bolsa de Valores | B3 07:47 Velocímetro do Sentimento da Bolsa08:08 A Bolsa está Barata?08:38 Consultoria de Investimentos

DeepSeek promete ser la alternativa más barata a OpenAI, pero ¿realmente está al mismo nivel? Analizamos si esta AI es una copia o una revolución, qué tan segura es usarla y qué significa para el futuro de la inteligencia artificial.  ¿Estamos ante una nueva potencia en AI o simplemente otro intento de China por controlar la tecnología? ⏰ Minutos  (0:59) ¿DeepSeek es realmente mejor?(1:28) ¿Es seguro usar DeepSeek?(3:04) ¿Triunfa el modelo Open Source?(6:22) ¿Se recupera Nvidia?(9:20) El poder político de la AI(9:50) El miedo de DeepSeek(10:40) Ventajas de DeepSeek(11:40) Democratización y desmonetización(12:46) Creatividad sobre presupuesto

Inteligencia Artificial, Donald Trump, Criptomonedas

El psicólogo José Antonio Galiani analiza el fenómeno de la “infoxicación” y sus efectos en la ansiedad y el bienestar emocional

Valora el hecho de que tengamos una fe clara y viva en el misterio de Dios Uno y Trino porque su costo fue la sangre de Nuestro Señor Jesucristo; no permitas que se pierda, al contrario que sea vida en tu vida.

Dejamos nuestro último episodio preguntándonos sobre los costos de construir una casa con derivados de la arcilla. ¡Resulta que es barato! Entonces, si es barato, ¿más personas han aprovechado la oportunidad de construir de esta manera? y ¿por qué no se ha popularizado en entornos urbanos? Para responder a estas preguntas, continuamos la conversación con Miguel Ángel Pérez, un bioconstructor de Baja, y hablamos sobre los costos de la construcción con arcilla. Tambien charlamos con Rachel Formanek, una neoyorquina que se mudó de California a Baja para encontrar condiciones de vida mejores y más asequibles. Por último, nos sentamos con Alex Ruiz, director de planificación urbana en Tecate y nos dió una nueva perspectiva sobre la viabilidad de la construcción con tierra en entornos urbanos. Foto de portada: Carlos Jaime and Cuahtémoc Herrera Sobre la temporada 6 Port of Entry tiene una nueva temporada con más historias de nuestra región fronteriza. En esta ocasión, estamos mostrando las perspectivas de algunos moldeadores y visionarios de las tierras fronterizas. Te contamos historias de personas que están impactando la región, y en algunos casos, el mundo con su trabajo e investigación; desde urbanismo hasta arquitectura, educación y política, y hasta arte y robótica. ¡Escucha nuestra nueva temporada! Redes sociales y contacto De KPBS, Port of Entry cuenta historias que cruzan fronteras. Para escuchar más historias visita www.portofentrypod.org Facebook: www.facebook.com/portofentrypodcast Instagram: www.instagram.com/portofentrypod Puedes apoyar nuestro podcast en www.kpbs.org/donate, escribe en la sección de regalos (gift section) “Port of Entry” y como agradecimiento podrás recibir un regalo. Si tu empresa u organización sin fines de lucro desea patrocinar nuestro podcast, envía un correo a corporatesupport@kpbs.org Nos encantaría recibir tu retroalimentación, envíanos un mensaje al 619-500-3197 o un correo a podcasts@kpbs.org con tus comentarios y/o preguntas sobre nuestro podcast. Créditos Hosts: Alan Lilienthal y Natalie González Escritor/Productor: Julio C. Ortiz Franco Productor Técnico/Diseñador Sonoro: Adrian Villalobos Productora Técnica: Rebecca Chacon Editora: Elma Gonzalez Lima Brandao y Melissa Sandoval Episodios traducidos por: Natalie González, Julio C. Ortíz Franco y Melissa Sandoval Directora de Programación de Audio y Operaciones: Lisa Morrisette This program is made possible, in part, by the Corporation for Public Broadcasting, a private corporation funded by the American people

Si te estabas convirtiendo en un vegano financiero, o sea que no comprabas carne porque no te alcanzaba, ahora podrás volver a comer vaca, se trata de un corte especial que no superará los 3 dólares.Escucha la triste historia de un tipo que se ganó 4 millones de dólares en la loteria ¿Qué le pasó? Mantente al día con los últimos de 'El Bueno, la Mala y el Feo'. ¡Suscríbete para no perderte ningún episodio!Ayúdanos a crecer dejándonos un review ¡Tu opinión es muy importante para nosotros!¿Conoces a alguien que amaría este episodio? ¡Compárteselo por WhatsApp, por texto, por Facebook, y ayúdanos a correr la voz!Escúchanos en Uforia App, Apple Podcasts, Spotify, y el canal de YouTube de Uforia Podcasts, o donde sea que escuchas tus podcasts.'El Bueno, la Mala y el Feo' es un podcast de Uforia Podcasts, la plataforma de audio de TelevisaUnivision.